Capmatinib
Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.
| Trivial name | INC280, NVP-INC280, INCB28060 |
| Catalog Number | S2788 |
| Molecular Formula | C22H23N3O4 |
| CAS# | 1029712-80-8 |
| Inchi | InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
| Inchi Key | AAKJLRGGTJKAMG-UHFFFAOYSA-N |
| SMILES | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC |
| Size | 10mg |
| Supplier Page | http://www.selleckchem.com/products/incb28060.html |
| Additional Information | https://file.selleck.cn/downloads/struct/INCB28060-chemical-structure-s2788.gif |